Assessing the stability of daptomycin in icodextrin-based peritoneal dialysis solution.

Chromatography daptomycin icodextrin-based PD quantitative analysis stability

Journal

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
ISSN: 1718-4304
Titre abrégé: Perit Dial Int
Pays: United States
ID NLM: 8904033

Informations de publication

Date de publication:
15 Oct 2024
Historique:
medline: 15 10 2024
pubmed: 15 10 2024
entrez: 15 10 2024
Statut: aheadofprint

Résumé

The stability of antimicrobials in peritonitis during peritoneal dialysis (PD) solutions is a critical factor influencing treatment success. This study investigated the stability of daptomycin (DAP) when combined with icodextrin-based PD solution, by measuring DAP concentrations and observing any structural changes. A dose of DAP (350 mg) was dissolved in 7 mL of saline in a clean bench. The solution was then injected into the large compartment (1,260 mL) of NICOPELIQ DAP maintained 90% of the initial concentration in NICOPELIC The findings from this stability study are expected to enhance the effectiveness of outpatient management and preparation for treating peritonitis using DAP.

Sections du résumé

BACKGROUND BACKGROUND
The stability of antimicrobials in peritonitis during peritoneal dialysis (PD) solutions is a critical factor influencing treatment success. This study investigated the stability of daptomycin (DAP) when combined with icodextrin-based PD solution, by measuring DAP concentrations and observing any structural changes.
METHODS METHODS
A dose of DAP (350 mg) was dissolved in 7 mL of saline in a clean bench. The solution was then injected into the large compartment (1,260 mL) of NICOPELIQ
RESULTS RESULTS
DAP maintained 90% of the initial concentration in NICOPELIC
CONCLUSIONS CONCLUSIONS
The findings from this stability study are expected to enhance the effectiveness of outpatient management and preparation for treating peritonitis using DAP.

Identifiants

pubmed: 39403764
doi: 10.1177/08968608241283526
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8968608241283526

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Hiroyuki Suzuki (H)

Division of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.

Kasumi Kudo (K)

Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
Division of Pharmacy, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

Takashi Uno (T)

Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.

Taisuke Konno (T)

Division of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.

Kouji Okada (K)

Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
Division of Clinical Pharmaceutics and Pharmacy Practice, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

Yasuyuki Agatsuma (Y)

Division of Pharmacy, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

Hitoshi Nakamura (H)

Division of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

Yuriko Murai (Y)

Division of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

Classifications MeSH